Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (NASDAQ: SNDX) has announced the granting of inducement awards under its 2023 Inducement Plan. The company, which focuses on developing cancer therapies, issued stock options to purchase up to 282,000 shares of common stock to 12 new employees on March 1, 2025.
The stock options feature a four-year vesting schedule, with 25% of shares vesting after the first year, followed by monthly vesting of 1/48th of the underlying shares over the subsequent 36 months. Continued employment with Syndax is required through the applicable vesting dates.
Syndax Pharmaceuticals (NASDAQ: SNDX) ha annunciato il conferimento di premi di incentivazione nell'ambito del suo Piano di Incentivazione 2023. L'azienda, che si concentra sullo sviluppo di terapie per il cancro, ha emesso opzioni su azioni per l'acquisto di fino a 282.000 azioni ordinarie a 12 nuovi dipendenti il 1 marzo 2025.
Le opzioni su azioni prevedono un programma di maturazione di quattro anni, con il 25% delle azioni che matura dopo il primo anno, seguito dalla maturazione mensile di 1/48 delle azioni sottostanti nei successivi 36 mesi. È richiesta la continuazione dell'impiego presso Syndax fino alle date di maturazione applicabili.
Syndax Pharmaceuticals (NASDAQ: SNDX) ha anunciado la concesión de premios de incentivo bajo su Plan de Incentivo 2023. La compañía, que se centra en el desarrollo de terapias contra el cáncer, emitió opciones sobre acciones para comprar hasta 282,000 acciones ordinarias a 12 nuevos empleados el 1 de marzo de 2025.
Las opciones sobre acciones cuentan con un cronograma de adquisición de cuatro años, con el 25% de las acciones adquiriéndose después del primer año, seguido por una adquisición mensual de 1/48 de las acciones subyacentes durante los siguientes 36 meses. Se requiere continuar el empleo con Syndax hasta las fechas de adquisición aplicables.
신닥스 제약 (NASDAQ: SNDX)은 2023 유인 계획에 따라 유인 보상을 부여한다고 발표했습니다. 암 치료제를 개발하는 데 주력하는 이 회사는 2025년 3월 1일에 12명의 신규 직원에게 282,000주의 보통주를 구매할 수 있는 주식 옵션을 발행했습니다.
주식 옵션은 4년의 베스팅 일정이 있으며, 첫 해가 끝난 후 25%의 주식이 베스팅되고, 이후 36개월 동안 매달 1/48의 주식이 베스팅됩니다. 해당 베스팅 날짜까지 신닥스에서 계속 근무해야 합니다.
Syndax Pharmaceuticals (NASDAQ: SNDX) a annoncé l'octroi de primes d'incitation dans le cadre de son Plan d'incitation 2023. L'entreprise, qui se concentre sur le développement de thérapies contre le cancer, a émis des options d'achat d'actions pour acquérir jusqu'à 282 000 actions ordinaires à 12 nouveaux employés le 1er mars 2025.
Les options d'achat d'actions comportent un calendrier d'acquisition de quatre ans, avec 25% des actions acquises après la première année, suivies d'une acquisition mensuelle de 1/48 des actions sous-jacentes au cours des 36 mois suivants. Un emploi continu chez Syndax est requis jusqu'aux dates d'acquisition applicables.
Syndax Pharmaceuticals (NASDAQ: SNDX) hat die Gewährung von Anreizprämien im Rahmen seines Anreizplans 2023 bekannt gegeben. Das Unternehmen, das sich auf die Entwicklung von Krebstherapien konzentriert, hat am 1. März 2025 12 neuen Mitarbeitern Aktienoptionen für den Erwerb von bis zu 282.000 Aktien ausgegeben.
Die Aktienoptionen haben einen vierjährigen Vesting-Zeitplan, wobei 25% der Aktien nach dem ersten Jahr, gefolgt von einer monatlichen Vesting von 1/48 der zugrunde liegenden Aktien in den folgenden 36 Monaten, fällig werden. Eine Fortsetzung der Anstellung bei Syndax ist bis zu den jeweiligen Vesting-Daten erforderlich.
- Employee retention strategy implemented through stock options
- Expansion of workforce with 12 new hires
- Potential shareholder dilution from 282,000 new shares
NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on March 1, 2025 the Company granted inducement awards to purchase up to 282,000 shares of common stock to 12 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
FAQ
How many shares were granted in Syndax Pharmaceuticals' March 2025 inducement awards?
What is the vesting schedule for SNDX's March 2025 inducement stock options?
How many employees received SNDX stock options in the March 2025 grant?
When did Syndax Pharmaceuticals (SNDX) issue the March 2025 inducement grants?
